These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 33712534)

  • 1. Diagnostic Contribution of Contrast-Enhanced CT as Compared with Unenhanced Low-Dose CT in PET/CT Staging and Treatment Response Assessment of
    Marchetti L; Perrucci L; Pellegrino F; Baroni L; Merlo A; Tilli M; Rambaldi I; Maietti E; Carnevale A; Bartolomei M; Giganti M
    J Nucl Med; 2021 Oct; 62(10):1372-1379. PubMed ID: 33712534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can full-dose contrast-enhanced CT be omitted from an FDG-PET/CT staging examination in newly diagnosed FDG-avid lymphoma?
    van Hamersvelt HP; Kwee TC; Fijnheer R; Beek FJ; de Klerk JM; Nievelstein RA
    J Comput Assist Tomogr; 2014; 38(4):620-5. PubMed ID: 24681861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicenter Comparison of Contrast-Enhanced FDG PET/CT and 64-Slice Multi-Detector-Row CT for Initial Staging and Response Evaluation at the End of Treatment in Patients With Lymphoma.
    Gómez León N; Delgado-Bolton RC; Del Campo Del Val L; Cabezas B; Arranz R; García M; Cannata J; González Ortega S; Pérez Sáez MÁ; López-Botet B; Rodríguez-Vigil B; Mateo M; Colletti PM; Rubello D; Carreras JL
    Clin Nucl Med; 2017 Aug; 42(8):595-602. PubMed ID: 28604477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic value of CT, PET and combined PET/CT performed with low-dose unenhanced CT and full-dose enhanced CT in the initial staging of lymphoma.
    Pinilla I; Gómez-León N; Del Campo-Del Val L; Hernandez-Maraver D; Rodríguez-Vigil B; Jover-Díaz R; Coya J
    Q J Nucl Med Mol Imaging; 2011 Oct; 55(5):567-75. PubMed ID: 21150860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Added value of pretreatment (18)F-FDG PET/CT for staging of advanced gastric cancer: Comparison with contrast-enhanced MDCT.
    Kawanaka Y; Kitajima K; Fukushima K; Mouri M; Doi H; Oshima T; Niwa H; Kaibe N; Sasako M; Tomita T; Miwa H; Hirota S
    Eur J Radiol; 2016 May; 85(5):989-95. PubMed ID: 27130061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
    Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
    Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PET/CT in malignant melanoma: contrast-enhanced CT versus plain low-dose CT.
    Pfluger T; Melzer HI; Schneider V; La Fougere C; Coppenrath E; Berking C; Bartenstein P; Weiss M
    Eur J Nucl Med Mol Imaging; 2011 May; 38(5):822-31. PubMed ID: 21210112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of diffusion-weighted MRI for pretherapeutic assessment and staging of lymphoma: results of a prospective study in 140 patients.
    Mayerhoefer ME; Karanikas G; Kletter K; Prosch H; Kiesewetter B; Skrabs C; Porpaczy E; Weber M; Pinker-Domenig K; Berzaczy D; Hoffmann M; Sillaber C; Jaeger U; Müllauer L; Simonitsch-Klupp I; Dolak W; Gaiger A; Ubl P; Lukas J; Raderer M
    Clin Cancer Res; 2014 Jun; 20(11):2984-93. PubMed ID: 24696320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Whole-body
    Gajjala SR; Hulikal N; Kadiyala S; Kottu R; Kalawat T
    Indian J Med Res; 2018 Mar; 147(3):256-262. PubMed ID: 29923514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of
    Panebianco M; Bagni O; Cenfra N; Mecarocci S; Ortu La Barbera E; Filippi L; Codacci-Pisanelli G; Biondi T; Laghi A; Cimino G
    Leuk Res; 2019 Jan; 76():48-52. PubMed ID: 30553980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PET/CT in lymphoma: prospective study of enhanced full-dose PET/CT versus unenhanced low-dose PET/CT.
    Rodríguez-Vigil B; Gómez-León N; Pinilla I; Hernández-Maraver D; Coya J; Martín-Curto L; Madero R
    J Nucl Med; 2006 Oct; 47(10):1643-8. PubMed ID: 17015900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diuretic 18F-FDG PET/CT imaging for detection and locoregional staging of urinary bladder cancer: prospective evaluation of a novel technique.
    Nayak B; Dogra PN; Naswa N; Kumar R
    Eur J Nucl Med Mol Imaging; 2013 Feb; 40(3):386-93. PubMed ID: 23179944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Role of 18F-FDG PET/CT in comparison with CECT for whole-body assessment of patients with esophageal cancer.].
    Altini C; Niccoli Asabella A; Lavelli V; Bianco G; Ungaro A; Pisani A; Merenda N; Ferrari C; Rubini G
    Recenti Prog Med; 2019 Mar; 110(3):144-150. PubMed ID: 30968855
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Verhagen MV; Menezes LJ; Neriman D; Watson TA; Punwani S; Taylor SA; Shankar A; Daw S; Humphries PD
    J Nucl Med; 2021 Nov; 62(11):1524-1530. PubMed ID: 33608429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic value of
    Tsuyoshi H; Tsujikawa T; Yamada S; Okazawa H; Yoshida Y
    Cancer Imaging; 2020 Oct; 20(1):75. PubMed ID: 33092631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of 18F-labelled fluoro-2-deoxyglucose-PET with conventional computed tomography for staging and response assessment in paediatric and adult patients with nodular lymphocyte-predominant Hodgkin's lymphoma.
    Rauf MS; Khan ZA; Zahir MN; Al-Sweedan S; Al-Kofide A; Alharthy H; Almugbel FA; Osmani A; Elhassan TAM; Khafaga Y; Maghfoor I; Akhtar S
    Nucl Med Commun; 2021 Aug; 42(8):899-906. PubMed ID: 33852535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical impact of contrast-enhanced computed tomography combined with low-dose (18)F-fluorodeoxyglucose positron emission tomography/computed tomography on routine lymphoma patient management.
    Chalaye J; Luciani A; Enache C; Beaussart P; Lhermite C; Evangelista E; Sasanelli M; Safar V; Meignan M; Haioun C; Rahmouni A; Itti E
    Leuk Lymphoma; 2014 Dec; 55(12):2887-92. PubMed ID: 24597987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 18F-FDG PET/CT role in staging of gastric carcinomas: comparison with conventional contrast enhancement computed tomography.
    Altini C; Niccoli Asabella A; Di Palo A; Fanelli M; Ferrari C; Moschetta M; Rubini G
    Medicine (Baltimore); 2015 May; 94(20):e864. PubMed ID: 25997066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Value of FDG PET/Contrast-Enhanced CT in Initial Staging of Colorectal Cancer - Comparison with Contrast-Enhanced CT.
    Kunawudhi A; Sereeborwornthanasak K; Promteangtrong C; Siripongpreeda B; Vanprom S; Chotipanich C
    Asian Pac J Cancer Prev; 2016; 17(8):4071-5. PubMed ID: 27644663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison between whole-body MRI with diffusion-weighted imaging and PET/CT in staging newly diagnosed FDG-avid lymphomas.
    Albano D; Patti C; La Grutta L; Agnello F; Grassedonio E; Mulè A; Cannizzaro G; Ficola U; Lagalla R; Midiri M; Galia M
    Eur J Radiol; 2016 Feb; 85(2):313-8. PubMed ID: 26781135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.